Phase I/IIa study of intratumoral/intracerebral or intravenous/intracerebral administration of Parvovirus H-1 (ParvOryx) in patients with progressive primary or recurrent glioblastoma multiforme: ParvOryx01 protocol.
(9/222)
(+info)
Pre-treatment with mesenchymal stem cells reduces ventilator-induced lung injury.
(10/222)
Bone marrow-derived mesenchymal stem cells (MSCs) reduce acute lung injury in animals challenged by bleomycin or bacterial lipopolysaccaride. It is not known, however, whether MSCs protect from ventilator-induced lung injury (VILI). This study investigated whether MSCs have a potential role in preventing or modulating VILI in healthy rats subjected to high-volume ventilation. 24 Sprague-Dawley rats (250-300 g) were subjected to high-volume mechanical ventilation (25 mL.kg(-1)). MSCs (5 x 10(6)) were intravenously or intratracheally administered (n=8 each) 30 min before starting over-ventilation and eight rats were MSC-untreated. Spontaneously breathing anesthetised rats (n=8) served as controls. After 3 h of over-ventilation or control the animals were sacrificed and lung tissue and bronchoalveolar lavage fluid (BALF) were sampled for further analysis. When compared with controls, MSC-untreated over-ventilated rats exhibited typical VILI features. Lung oedema, histological lung injury index, concentrations of total protein, interleukin-1beta, macrophage inflammatory protein-2 and number of neutrophils in BALF and vascular cell adhesion protein-1 in lung tissue significantly increased in over-ventilated rats. All these indices of VILI moved significantly towards normalisation in the rats treated with MSCs, whether intravenously or intratracheally. Both local and systemic pre-treatment with MSCs reduced VILI in a rat model. (+info)
Population pharmacokinetics of clindamycin orally and intravenously administered in patients with osteomyelitis.
(11/222)
(+info)
Intraoperative fluorescence imaging of peripheral and central nerves through a myelin-selective contrast agent.
(12/222)
(+info)
Human microdose evaluation of the novel EP1 receptor antagonist GSK269984A.
(13/222)
(+info)
Continuous parenteral and enteral nutrition induces metabolic dysfunction in neonatal pigs.
(14/222)
(+info)
Off-target platelet activation in macaques unique to a therapeutic monoclonal antibody.
(15/222)
(+info)
Barriers to an early switch from intravenous to oral antibiotic therapy in hospitalised patients with CAP.
(16/222)
(+info)